POINT Biopharma Receives U.S. Nuclear Regulatory Commission Materials License for Indiana Facility
POINT Biopharma Inc. (POINT), a radiopharmaceutical company dedicated to bringing the many benefits of precision radioligand therapy to cancer patients, announced today that the U.S.…
Read More...
Read More...